OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL

Abstract: Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, 4-1BB chimeric antigen receptor (CAR) T-cell product approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We present the OUTREACH primary analysis, evaluating the safety and efficacy of outpatient monitori...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yuliya Linhares, Cesar O. Freytes, Mohamad Cherry, Carlos Bachier, Michael Maris, Daanish Hoda, Juan C. Varela, Courtney Bellomo, Scott Cross, James Essell, Suzanne Fanning, Howard Terebelo, Habte Yimer, Jay Courtright, Jeff P. Sharman, Ana Kostic, Min Vedal, Ken Ogasawara, Ariel Avilion, Ricardo Espinola, Brenda Yuan, Bassam Mattar
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2024-12-01
Col·lecció:	Blood Advances
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2473952924005718
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!